Social media's age assurance has emerged as one of the most debated topics in trust and safety. In this guest commentary, Sacha Lazimi of Yubo shares tips for setting new standards in social media and ...
Following New Balance ‘s reissue of the retro 1000 model in 2024, the Boston-based footwear brand has teamed up with BEAMS ...
Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 12.39%, which has investors questioning if this is right time ...
Of all the antiquated axioms in the American lexicon, “the fix is in” is among the most broadly understood. Just about everyone knows what it means, but I looked up its etymology, anyway. According to ...
The impairment, often associated with long Covid, doesn’t mean you’re more likely to get dementia or Alzheimer’s disease.
Julie Reiner helped build the cocktail culture we know and love today, and one drink exemplifies her approach.
Analysts have been eager to weigh in on the Healthcare sector with new ratings on HilleVax, Inc (HLVX – Research Report), Lexicon ...
Swiss National Bank increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 34.4% during the 4th ...
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
As companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive license to a preclinical-stage, ...
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.
In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback